直接抗病毒药物(DAA)在丙肝治疗中的临床应用进展  

The Clinical application progress of direct antiviral drugs(DAA) in the treatment of hepatitis C

作　　者：韩杰[1] 郝竟琳 田姗[1] 付萌萌 张静姝[1] 朱姗薇[1] Han jie;Hao jinglin;Tian shan;Fu mengmeng;Zhang Jingshu;Zhu shanwe(302th hospital of PL)

机构地区：[1]解放军第302医院,100039

出　　处：《首都食品与医药》2018年第17期42-43,共2页Capital Food Medicine

摘　　要：丙型病毒性肝炎(简称丙肝)是由丙型肝炎病毒(HCV)引起的导致肝炎发生炎症坏死和纤维化的传染病,部分丙型肝炎患者可以发展为肝硬化甚至肝癌。随着直接抗病毒药物(DAA)在我国陆续获批上市,为这一公共卫生问题带来了突破性的进展。本文从丙型肝炎的治疗目标入手,通过介绍DAA药物的作用靶点、联合用药及我院已用于临床的两种DAA药物,分析其优势及局限,指出DAA治疗方案在大大提升丙肝治愈率的同时,也可有效改善患者愈后,提高生活质量,值得临床推广。Hepatitis C virus （HCV） is an infectious disease caused by Hepatitis C virus （HCV）,it can cause inflammation necrosis and fibrosis. Some patients with hepatitis C can develop cirrhosis and liver cancer. With the success of the direct antiviral drugs （DAA） marketed in China,public health has been brought about.This article starts from the therapeutic target of hepatitis C,introduces the DAA drug target,combination therapy and two kinds of DAA drugs which have been used clinically in our hospital,analyzes its advantages and limitations,points out that the DAA treatment program not only greatly improves the cure rate of hepatitis C At the same time,but also effectively improve the prognosis of patients and improve the quality of life,it is worth promoting in clinical.

关 键 词：直接抗病毒药物 丙肝治疗 临床应用 

分 类 号：R512.6[医药卫生—内科学]